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ABSTRACT 
Centronuclear myopathies are early-onset muscle diseases caused by mutations in 
several genes including MTM1, DNM2, BIN1, RYR1 and TTN. The most severe and 
often fatal X-linked form of myotubular myopathy (XLMTM) is caused by mutations 
in the gene encoding the ubiquitous lipid phosphatase myotubularin, an enzyme 
specifically dephosphorylating phosphatidylinositol-3-phosphate and 
phosphatidylinositol-3,5-bisphosphate. Because XLMTM patients have a 
predominantly muscle-specific phenotype a number of pathogenic mechanisms have 
been proposed, including a direct effect of the accumulated lipid on the skeletal 
muscle calcium channel ryanodine receptor 1, a negative effect on the structure of 
intracellular organelles and defective autophagy. Animal models knocked out for 
MTM1 show severe reduction of ryanodine receptor 1 mediated calcium release but, 
since knocking out genes in animal models does not necessarily replicate the human 
phenotype, we considered it important to study directly the effect of MTM1 mutations 
on patient muscle cells. The results of the present study show that at the level of 
myotubes MTM1 mutations do not dramatically affect calcium homeostasis and 
calcium release mediated through the ryanodine receptor 1, though they do affect 
myotube size and nuclear content. On the other hand, mature muscles such as those 
obtained from patient muscle biopsies exhibit a significant decrease in expression of 
the ryanodine receptor 1, a decrease in muscle-specific microRNAs and a 
considerable up-regulation of histone deacetylase-4. We hypothesize that the latter 
events consequent to the primary genetic mutation, are the cause of the severe 
decrease in muscle strength that characterizes these patients.     
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INTRODUCTION 
  Centronuclear myopathies are rare muscle disorders caused by mutations in 
several genes including MTM1, DNM2, BIN1, RYR1 and TTN (1-7) and are associated 
with autosomal dominant, autosomal recessive and X-linked modes of inheritance. 
The X-linked form (XLMTM, MIM #310400) is the most severe and is characterized 
by profound muscle weakness, severe bulbar and respiratory involvement. Symptoms 
are typically present at birth and without ventilator support most affected males die 
within the first year of life, though some infants have a milder presentation with less 
severe onset and survive into early childhood or adolescence (1, 2, 8, 9). Muscle 
biopsies typically show the presence of numerous centralized nuclei, predominance of 
often atrophic type I fibres, disorganization of the myofibrillar network and, 
particularly in more mildly affected males and manifesting females, “necklace fibres” 
(10-12). MTM1 encodes for myotubularin, a lipid phosphatase that specifically 
dephosphorylates phosphatidylinositol-3-phosphate (PI(3)P) and 
phosphatidinylinositol-3,5-bisphosphate (PI(3,5)P2) to produce PI and PI(5)P, 
respectively (for review see 3). Though myotubularin is ubiquitously expressed, 
mutations in the MTM1 gene result in a selective skeletal muscle phenotype. One 
reason for this may be the lack of expression of potentially compensatory 
myotubularin related proteins in skeletal muscle in contrast to their expression in 
other tissues (13); however, skeletal muscles expresses MIP/MTMR14 a 
phosphatidylinositol phosphate phosphatase of apparent similar function as 
myotubularin and mice knocked out for MIP/MTMR14 also exhibit a severe muscle 
phenotype (14), raising the possibility that altered phosphatidylinositol lipid 
metabolism specifically interferes with physiological skeletal muscle function(s) 
and/or development (15). To date more than 200 different MTM1 mutations 
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(including missense, frameshift and small deletions) have been identified in XLMTM 
patients with most mutations predicted to affect enzymatic activity (9, 10, 16-19).  
In humans, 15 genes encode for different myotubularins with most members of this 
family playing important roles in membrane trafficking, movement of intracellular 
vesicles, autophagy and phagocytosis (3, 20-22). In addition to their role as 
phosphatases, myotubularins also contain functional domains promoting protein-
protein or lipid-protein interactions suggesting that the lack of the myotubularin 
complex may additionally be involved in disease pathogenicity (18,19). Muscles from 
5 week old Mtm1-null mice are 50% lighter compared to controls, show 
disorganization of triadic architecture, longitudinally oriented tubules and a 
significant decrease in RyR1 and Cav1.1 protein content (23). Furthermore, Mtm1-null 
mice and zebrafish exhibit abnormal Ca2+ homeostasis and impaired excitation-
contraction coupling (ECC) (13, 23). ECC is the process occurring in striated muscles 
whereby an electrical signal, the depolarization of the plasma membrane, is converted 
into a chemical signal, that is an increase in the myoplasmic calcium concentration, 
leading to muscle contraction (24, 25). The two key players of skeletal muscle ECC 
are the dihydropyridine receptor (DHPR), a multi-protein complex made up of 5 
subunits (Cav1.1, ß1,  2, and ∂) (26) which is localized on the transverse 
tubules where it acts as a voltage sensor and the ryanodine receptor (RyR1), a 
macromolecular complex of > 2.5 MDa made up of 4 homotetramers, that constitute 
the Ca2+ release channel of the sarcoplasmic reticulum (SR) (24, 27). Activation of 
the DHPR induces conformational changes that promote its interaction with the 
RyR1; this leads to the opening of the RyR1 and to the release of Ca2+ from the SR 
stores. In order to occur rapidly (few milliseconds) and efficiently, ECC relies on a 
highly sophisticated and well-defined subcellular architecture with each DHPR facing 
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a RyR1 in a highly organized conformation (24, 27) thus a reduction of RyR1 protein 
content or disorganization of triadic architecture should negatively affect ECC. 
Indeed, patients with recessive RYR1 mutations exhibiting a severe reduction in RyR1 
protein content are affected by congenital muscle disorders (28-30), and animal 
models knocked out for structural SR proteins show reduced muscle strength (31-33). 
In a recent study we investigated the mechanism leading to reduced RyR1 expression 
in patients with recessive RYR1-related congenital myopathies and found that a 
pathological epigenetic loop involving changes in the expression of microRNAs and 
class II histone deacetylases (HDACs) is activated (34). Since muscles from Mtm1-
null mice show reduced RyR1 expression we hypothesize that similar epigenetic 
changes might occur in the muscles of patients with XLMTM.  
In the present study we investigated the physiological, biochemical and 
epigenetic characteristics of skeletal muscles from patients with MTM1 mutations. 
Surprisingly ECC in myotubes from MTM1-mutated patients was unaffected while 
there were important biochemical and epigenetic modifications occurring in mature 
muscle fibres. The findings of this and of our recent study (34) indicate that common 
epigenetic changes consequent to the primary genetic defect are activated in different 
congenital myopathies. Targeting such secondary modifications could potentially 
improve the muscle function in patients affected by congenital myopathies with the 
common feature of reduced RyR1 protein content. 
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RESULTS 
Patient description 
The genotypic and phenotypic characteristics of the patients enrolled in the 
present study are shown in Table 1. Five of six patients either had frameshift 
mutations, deletions or premature stop codons and only one patient (NH14-1816) 
carried a missense mutation. The recurrent p.Arg241Cys mutation shows phenotypic 
variation and has previously been identified in severely, moderately and mildly 
affected patients (16-19). The patient carrying the p.Arg241Cys mutation investigated 
in this study was severely affected, requiring ventilation and a tracheostomy. 
Surprisingly, patient N° 6499 who carried a 2 nucleotide deletion in exon 14 which 
encodes part of the SID (SET interaction domain) was only moderately affected; he 
was nasogastric tube / gastrostomy fed, did not require ventilator support, achieved 
the ability to sit unsupported, but had swallowing difficulty with oral secretions and 
suffered a respiratory arrest at age three. Three patients died at 4, 6 months and 3 
years. Three patients are >1 year old but are severely affected and require mechanical 
ventilation. These results are in line with previous reports suggesting that in general, 
truncating mutations are associated with a severe phenotype. In order to verify 
whether potential genotype-phenotype correlations could be identified at the 
molecular level we investigated physiological, cellular and biochemical changes 
occurring in the muscle cells of the affected patients.  
 
Immunohistochemistry and functional studies on primary muscle cells 
PI phospholipids are present in specific subcellular membrane compartments 
and organelles and alterations in their distribution and content may affect cell size, 
growth and appearance. We first examined the gross morphology of differentiated 
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myotubes form healthy controls and patients harbouring MTM1 mutations. Muscle 
cells were only available from patients having either a frameshift mutation, deletion 
of the 5’end of the gene, or a premature stop codon (Supplementary Table 1) all of 
which are expected to result in lack of myotubularin protein expression. Figure 1A 
shows a brightfield image of the cells from a healthy control (top panel) and a patient 
(bottom panel), and panels B-D show the average area, number of nuclei and 
nuclei/area, respectively. As shown myotubes from the XLMTM patients were 
significantly smaller and had fewer nuclei than myotubes from healthy controls, 
though the number of nuclei/cell area remained unchanged. These results suggest that 
the lack of myotubularin negatively affects cell growth. 
Since there are no commercial antibodies recognizing PI(3,5)P2, one of the 
substrates of myotubularin, we performed immunofluorescence analysis on myotubes 
to check for alterations in the subcellular distribution and content of PI3P as well as 
PI(3,4)P2, a PI that can either be phosphorylated to yield PI(3,4,5)P3 or 
dephosphorylated to yield PI4P and then potentially re-converted to PI3P (35). Figure 
2 shows the localization of the two phospholipids in myotubes from a healthy control 
(Fig.2A panels a and e) and a patient with XLMTM (Fig.2A panels c and g). Panels b, 
d, f and h of figure 2 show the cellular distribution of actin (phalloidin, green), the PI 
phospholipid (red) and nuclei (DAPI, blue). The commercial antibodies against the 
two phospholipids show background staining on areas of the coverslips devoid of any 
cells; these may be either lipid aggregates or fragments of membranes of cells that 
have detached. Nevertheless there is a punctuated staining in correspondence of the 
myotubes and as far as the gross appearance and distribution of the phospholipids is 
concerned, these were similar in control and patient myotubes, with PI3P having a 
punctuated, uniformly distributed fluorescence within a membrane compartment, and 
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PI(3,4)P2 having a more patchy appearance, concentrated within particular membrane 
domains. More detailed examination revealed quantitative differences in the amount 
of PI3P present as determined by fluorescence intensity; in particular there was ~ a 2 
fold increase in the mean fluorescence intensity (measured as arbitrary units) 
associated with PI3P but no significant change in the level of PI(3,4)P2 in myotubes 
from patients versus controls (Fig. 2B).  
In muscle fibres from Mtm1-null zebrafish and 5 weeks old Mtm1-null mice 
profound changes in the distribution of RyR1 and Cav1.1 have been described, with 
the absence of immunolabelling in some regions and disruption of the triad 
architecture (13, 23). We therefore examined the distribution of RyR1 and Cav1.1 in 
patient myotubes; even though the latter cells do not achieve the degree of 
differentiation typical of mature fibres (36), a drastic decrease or mis-localization of 
these proteins would be observable by confocal microscopy. However, no substantial 
changes in the subcellular distribution of RyR1 (Fig. 3A, panels a and d) and Cav1.1 
(Fig. 3A panels b and e) were observed. More importantly, quantification of RyR1 
and Cav1.1 protein by Western blot revealed that if anything, the content of these two 
proteins was increased in myotubes from patients compared to controls (Fig. 3 B and 
C). Figure 3B and C also show that the protein content of HDAC-4 is similar in 
myotubes from controls and patients while the protein myotubularin is present in 
myotubes from healthy controls but is absent from myotubes from XLMTM patients 
(Fig. 3 B and C). 
In previous reports it was shown that muscle fibres from the Mtm1-null mice 
show impaired ECC (23). In order to verify if this was also the case in cells from 
human MTM1-mutant patients we investigated the calcium homeostasis and ECC 
characteristics of myotubes from 3 patients (2 carrying frameshift mutations and 1 
 9 
carrying a premature stop codon) and compared them to those of myotubes from 
healthy controls (pooled results from 3 different individuals). There was a small but 
significant decrease in the resting [Ca2+]i in myotubes from patients harbouring 
MTM1 mutations (Fig. 4A), whereas the total amount of rapidly releasable Ca2+ 
within intracellular stores calculated as area under the curve (AUC) after addition of 1 
µM thapsigargin and 1 µM ionomycin in Krebs Ringer containing 100 µM La3+ and 
0.5 mM EGTA (34, 36), was similar in control and patient myotubes (Fig. 4B). Figure 
4C shows a representative trace of changes in the [Ca2+]i in response to 60 mM KCl in 
Krebs Ringer containing 100 µM La3+. The peak Ca2+ elicited by 600 µM 4-cmc and 
60 mM KCl (Fig. 4D and E, respectively) were similar in myotubes from controls and 
patients. There were no significant differences in the dose response curves to 4-cmc 
and KCl (see also Supplementary Fig.1), the EC50 being 351.4±65.6 and 387.4±33.7 
µM for 4-cmc and 16.1±4.2 and 12.0±3.8 mM for KCl in control and patient 
myotubes, respectively. In conclusion, these results indicate that at the level of 
myotubes, mutations in MTM1 cause a 2 fold increase in PI3P, a decrease in myotube 
size and nuclear content but no major alterations in the distribution of PI3P/PI(3,4)P2, 
nor in the proteins involved in ECC. In the next series of experiments, we investigated 
if biochemical changes were occurring in mature patient muscle fibres. 
 
Biochemical analysis and epigenetic modifications in muscles from patients with 
XLMTM 
The content of RyR1, Cav1.1 and class II histone deacetylases (HDAC-4 and 
HDAC-5) was investigated by immunoblotting on total muscle homogenates from 
patients and healthy controls. We assessed class II HDACs since a decrease in RyR1 
protein level was observed in the muscle of patients with CNM due to recessive RYR1 
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mutations and this is accompanied by a significant increase in HDAC-4 and HDAC-5 
protein content (34). Figure 5A and C shows representative Western blots and figure 
5B and D shows the relative protein content of RyR1 and Cav1.1 normalized to 
MyHC content. The anti-MyHC antibody that was used recognizes all isoforms, so 
that the results are not affected by the potential expression of different MyHC 
isoforms. Protein quantification could not be performed on biopsies from all patients 
due to the lack of sufficient biological material. Nevertheless, qPCR analysis was 
performed on muscle samples from all patients (see next paragraph). The results 
depicted in figure 5 A-D confirm that both RyR1 and Cav1.1 protein content was 
significantly reduced in most mature human MTM1-mutated muscle fibres whereas 
the levels of HDAC-4 were significantly increased, while those of HDAC-5 were not 
as elevated. Of interest, patient NH13-0078 carrying the p.Tyr198X mutation had 
RyR1 and HDAC-4 protein levels that were similar to those of controls, whereas the 
moderately affected patient carrying the c.1508_1509 deletion (N° 6499) had HDAC-
4 protein levels that were >200 times higher than in controls. Protein and transcript 
levels were not always concordant (see next paragraphs). 
In patients with recessive RYR1 mutations increased class II HDAC content was 
paralleled by an increase in the transcripts encoding DNA methyltransferase 1 
(DNMT1), and DNA methyltransferases 2 (now called tRNA aspartic acid 
methyltransferase 1, or TRDMT1) (34). We therefore also investigated whether 
similar changes occur in muscles of patients with MTM1 mutations. Figure 5 E shows 
that a significant increase (approximately 10 fold) in both in DNMT1 and TRDMT1 
transcripts occurs in the muscles of the XLMTM patients. Note that in figure 5E the 
values for patients 0805 and 7457 have not been plotted since they were > 1000 fold 
higher than in control muscles; however, all expression values are presented in panel 
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F of figure 5 where the expression levels of the transcripts encoding HDAC4, RYR1, 
MTM1, DNMT1 and TRDMT1 of each patient compared to levels observed in biopsies 
from control individuals are shown. The latter values were used as a reference and set 
to 1 (Fig. 5F). A decrease in transcript is indicated in red and an increase in green and 
the colour-code scale is shown in the right hand column. RYR1 transcripts were 
significantly reduced by more than 50% in muscle biopsies from all patients 
examined and HDAC4 transcripts were significantly elevated in all patients. The 
increase in HDAC4 was paralleled by increased expression of the DNA methylating 
enzyme transcripts DNMT1 and TRDMT1. Of note, patients 0805 and 7457 were 
particularly striking since they exhibited > 40 fold increased levels of MTM1, the 
highest levels of HDAC4 transcripts and >700 fold levels of DNMT1 and TRDMT1. 
Curiously, at the myotube level HDAC-4 was expressed to similar levels in myotubes 
from healthy controls and XLMTM patients (see Fig. 3 panels B and C) indicating 
that these epigenetic modifications only occur in mature muscle tissue.  
As mentioned above, the relative expression of HDAC-4 protein and transcript level 
did not always correlate, particularly in the case of patient 6499 where HDAC-4 
protein was elevated approximately 200 fold but whose transcript was increased only 
3 times. Similar discrepancies were found for MTM1 transcript and protein levels: 
mRNA levels were decreased in 3 patients (N° 6212, 0078 and 6499) and increased in 
3, (N° 1816, 0805 and 7457) whereas the myotubularin protein was absent in the 
muscles of patients N° 6212, 0805 and 0078 (Supplementary fig. 2A). Insufficient 
quantities of biological material precluded the assessment of myotubularin protein in 
the biopsies from the remaining patients. PI3P levels were significantly elevated in 
muscles of all XLMTM patients tested (patients N° 0078, 1816, 0805, 6212 and 6499. 
Supplementary figure 2B) confirming the results obtained on myotubes (figure 2) as 
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well as previous observation that cells from patients or animal models knocked out or 
knocked in for human MTM1 mutations have higher PI3P levels (13, 23, 37, 38). 
We focused the next series of experiments on determining the content of 
microRNAs (miRs). Because of the limited amount of biological material, we 
measured the expression levels of a selected group of muscle-specific miR transcripts, 
namely miR-1, miR-133, miR-206 and the muscle enriched miR-486 as well as miR-
22, miR-124 which are predicted to bind to the 3’UTR of the RYR1 gene and several 
miRs predicted to bind to the human MTM1. Figure 6 shows the mean expression 
levels and Supplementary Table 2 shows miR levels in individual patients. As shown, 
most miRs were significantly down-regulated, except for miR-124, 128 and 206 that 
showed greater variability and were not always changed when compared to levels in 
biopsies from healthy controls. Of interest patients N° 1816, 0805 and 7457 who were 
all severely affected showed down regulation of all the miRs, down-regulation of 
RYR1 transcript and up-regulation of HDAC4 transcript. 
 
Muscles from XLMTM patients are different from foetal muscles  
Data from the literature suggest that muscles from XLMTM patients revert to 
a “foetal” phenotype (15) a hypothesis that is compatible with the up-regulation of 
HDAC-4 and down-regulation of RyR1 and of muscle-specific miRs. Since we had 
available small amounts of muscle samples from non-affected 13.8-20.2 week old 
foetuses, we used these to assess the content of several proteins. Not unexpectedly the 
foetal samples contain very high levels of HDAC-4 protein (Supplementary Figure 3) 
and HDAC-5 but because of the large variability and small sample size this did not 
achieve statistical significance (Fig. 7A); on the other hand, the relative content of 
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RyR1 was significantly reduced while that of Cav1.1 was either unchanged (1 sample) 
or reduced (1 sample) (Fig. 7B).  
Since the MyHC isoform expressed by a muscle is a sensitive and accepted 
indicator of muscle fibre type we performed high-resolution gel electrophoresis on 
control, foetal and patient muscle extracts to verify their degree of development, using 
conditions that allow separation of the different MyHC isoforms (39, 40). Figure 7C 
shows a representative gel stained with Coomassie Blue showing the separation of 
MyHC isoforms (I, IIa and IIx) in human muscle biopsies. As shown the muscle 
sample from a control shows the 3 bands corresponding to MyHC I, IIa and IIx, while 
in foetal muscle the MyHC I band corresponding to the slow isoform is clearly 
present, together with a band having an electrophoretic mobility similar to that of 
MyHC IIa. The MyHC isoform present in muscles biopsies from the 5 patients 
carrying MTM1 mutations were not uniform, showing the presence of bands having 
different electrophoretic mobility, with the biopsy from patient MTM1 0805 being 
more similar to that of the control individual. The upper band present in foetal muscle 
(and in the muscles from the XLMTM patients) having an electrophoretic mobility 
similar to MyHC IIa, may correspond to the embryonic/foetal isoform. We therefore 
also performed a Western blot using an antibody specific for MyHC3 
(embryonic/foetal isoform). Figure 7 D shows that MyHC3 is virtually absent from 
control muscles, whereas a strong immunoreactive band is visible in homogenates 
from the foetal muscles. A band showing immunoreactivity with anti-MyHC3 
antibodies is present in the muscle biopsy from patient MTM1 6212 but not with 
biopsies from patients MTM1 0805,1816 and 078 indicating that the latter patients do 
not express detectable levels of embryonic/foetal MyHC.  
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DISCUSSION 
In the present study we investigated skeletal muscle samples from 6 patients 
affected by XLMTM and assessed the impact of MTM1 mutations on ECC. Our 
results show that MTM1 mutations do not directly impinge on ECC since at the level 
of myotubes the absence of myotubularin does not significantly affect calcium 
homeostasis but rather affects cell morphology and size. This contrasts with what is 
observed in mature muscle fibres, where the expression of key proteins involved in 
ECC is significantly down-regulated. In addition, we show that in muscles from 
XLMTM patients HDAC-4 is significantly up-regulated. We propose that secondary 
modifications occurring as a consequence of MTM1 mutations affect the expression of 
muscle-specific transcripts and are responsible at least in part for the muscle 
weakness seen in these patients.  
In order to assess ECC we used muscle cells explanted from the patient’s 
biopsies, an experimental model we have previously used to investigate calcium 
homeostasis in cells from patients affected by other congenital muscle diseases (28, 
34, 41, 42). Such a system offers several advantages, including (i) endogenous 
expression of the patient’s mutation without the need to transfect or virally infect 
cells, (ii) ease with which cells are grown and differentiated into myotubes and (iii) 
amenability of cells for studies on basic calcium homeostasis. The main drawback of 
this model is that myotubes do not differentiate into fully developed muscle fibres and 
that they will also express, if present, other mutations present in the patient’s genome. 
From a morphological point of view, the most striking difference was the appearance 
of the myotubes, their smaller size and number of nuclei, though the average number 
of nuclei corrected per cell area remained unchanged. This finding contrasts an earlier 
report suggesting that myotubes from XLMTM patients are indistinguishable as far as 
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size, shape or nuclear distribution are concerned, compared to myotubes from healthy 
controls (43). Such a discrepancy may relate to nature of the mutation, muscle of 
origin and growth conditions. All the myotubes used in the present study were from 
quadriceps and the mutations lead to undetectable levels of myotubularin, while in the 
study of Dorchies et al., muscles cells were obtained from different muscle tissues 
(leg, arm, quadriceps) and from patients with severe and mild phenotypes (43).   
Although the exact causes of such morphological changes are difficult to 
uncover, they may relate to accumulation of PIs within subcellular membrane 
domains, alterations of autophagy, or inappropriate activation of mTOR (44-48). As 
far as accumulation of specific PIs is concerned, myoblasts deficient in 
phosphoinositide phosphatases were reported to contain a two-fold increase in 
PI3P/PI(3,5)P2, (14, 37, 38), a result confirmed in the present study where we also 
show that the PI3P content in mature muscle is significantly increased. Generally, PI 
lipids constitute less than 15% of the total cellular phospholipids with PI4P and 
PI(4,5)P2 representing the major forms in mammalian cells (35, 44, 45). Thus while it 
is true that PI can be metabolically interconverted in vitro, different PI species are not 
equally present within the cell, do not share the same subcellular distribution and can 
diffuse within but not between membranes unless assisted by specific transfer 
proteins. For example PI(4,5)P2 and PI(3,4,5)P3 are concentrated in the plasma 
membrane, PI(3,4)P2 is in the plasma membrane as well as early endocytic vesicles 
and PI3P is concentrated in early endosomes (35, 45).  Thus accumulation of PI3P as 
caused by MTM1 mutations, could potentially interfere with early endosomal 
trafficking as recently confirmed by Ketel and co-workers (20). 
An alternative possibility is that PI3P accumulation affects autophagy since 
this lipid plays a major role in the initiation of, and modulation of autophagy (47, 48) 
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or affects the IGF1R/AKT pathway that closely controls mTOR activation and thus 
cell growth, which was shown to be dysregulated in muscles from Mtm1-/- mice (49).  
One of the main questions relating to PI metabolism and disease 
pathomechanism(s) is whether there is a functional link between alterations of 
phospholipid metabolism and skeletal muscle function. This is particularly relevant 
since patients carrying mutations in genes encoding enzymes involved in lipid 
metabolism have a muscle-specific phenotype. Recent data supports a direct effect of 
certain PI lipids on calcium homeostasis. In particular (i) myotubes from mice 
deficient in MTMR14 exhibit spontaneous Ca2+ leak due to the binding of PI(3,5)P2 
and PI(3,4)P2 to RyR1 which promotes its activation (14); (ii) PI3P and PI(3,5)P2, 
directly depress voltage activated Ca2+ release when injected into mouse FDB fibres 
(50); (iii) depletion of PI(4,5)P2 in the transverse tubules impairs SR Ca
2+ release (51) 
and (iv) the endoplasmic reticulum and sarcoplasmic reticulum of animal models 
knocked out for MTM1 and MTMR14 show profound structural changes and 
dysfunction of ECC (13, 14, 23, 38). For these reasons we were surprised to find that 
the calcium homeostasis and ECC of myotubes from patients with MTM1 mutations 
were similar to those of control myotubes. Indeed, we observed no changes in levels 
of the SR Ca2+ stores, nor in the peak Ca2+ elicited by depolarization or by direct 
pharmacological activation of the RyR1. We did observe a small decrease in the 
resting [Ca2+]i but this is most likely due to the degree of differentiation of the 
myotubes rather than to a direct effect on ECC. In fact, Western blot analysis showed 
that myotubes from the XLMTM patients express higher levels of RyR1 and Cav1.1 
compared to control myotubes, though the subcellular localization of both proteins 
was similar in patient and control cells. Importantly, the lack of effect on Ca2+ 
homeostasis is not due to the lack of myotubularin expression at the level of the 
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myotubes as opposed to mature muscle, since Western blot analysis showed that the 
immunopositive band was present in protein extracts of myotubes from controls (but 
not from patients).  
This observed lack of effect of MTM1 mutations on the ECC of myotubes was 
puzzling especially considering that muscle biopsies from the same patients and 
muscles from the Mtm1-/- mice showed significantly lower levels of RyR1 and Cav1.1 
proteins and that FDB fibres from the Mtm1-/- mice showed a much smaller 
depolarization induced peak Ca2+ transient compared to their wild type littermates 
(23). This apparent inconsistency between myotubes and mature muscle fibres 
indicates that: (i) the lack of myotubularin does not directly affect ECC and (ii) 
requires fully developed mature fibres in order to show a functional effect. This is 
reminiscent of what occurs in muscles from patients with recessive RYR1 mutations, 
where no apparent effect on Ca2+ homeostasis was seen at the myotube level but 
where a significant decrease of ECC proteins in muscle homogenates was found (34). 
In the latter case epigenetic modifications were responsible at least in part, for the 
decrease in ECC protein expression. Interestingly, in muscle biopsies from the 
XLMTM patients RYR1 transcript content was severely reduced, HDAC4, DNMT1 
and TRDMT1 levels were significantly increased and most muscle specific miRs were 
down-regulated. Although in the present study the sample number was too small to 
draw definite conclusions and make specific correlations, they may explain 
phenotypic differences observed in patients. Indeed, patients carrying mutations such 
as the p.R241C substitution, or patients carrying deletions of exon 1 have been 
reported as being severely, moderately or mildly affected (16-19) while some patients 
carrying nonsense mutations predicted to result in a truncated enzyme-dead protein, 
were surprisingly only moderately affected (18,19).  
 18 
An important additional observation of the present study relates to the 
amounts of protein and transcript levels within the muscle biopsy that did not always 
match. Lack of correlation between transcripts and proteins have been reported by a 
number of authors and may relate to transcript/protein stability, stability of the 
transcript versus selected housekeeping gene, effect of post-translational 
modifications on protein turnover (52-55).  However, lack of correlation of the same 
protein/transcripts in the same tissue in some individuals but not others, indicates that 
different mechanisms are activated in response to mutations, stress or environmental 
factors in different cells and that these will result in “phenotypic variability”. One 
such mechanism linking regulation of gene expression to external or environmental 
factors involves a group of enzymes known HDACs that can be recruited in 
association with DNA-methylation to repress transcription by deacetylating core 
histones (56). Class II HDACs are expressed in skeletal muscle and affect myogenesis 
by sequestering mef2, a master trans-activator of skeletal muscle gene expression (57, 
58). Mef2 sequestration results in blockage of mef2 dependent gene transcription, 
including transcription of muscle specific miRs such as miR1 and miR133 (59, 60) 
and this in combination with the increased expression of DNA methylating enzymes 
could be a contributing factor to the fast to slow fibre type conversion, triadic 
disarrangement and phenotype of a muscle with “foetal-like” characteristics. Clearly 
more work needs to be carried out in the future and it is important that transcriptome 
analysis be validated at the protein level and more detailed characterization of the 
MyHC isoform expressed be performed whenever possible. 
Taken together the results of this and our previous study (34) raise the 
interesting possibility that the epigenetic modifications taking place in skeletal muscle 
as a consequence of mutations in different genes involved in congenital myopathies 
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are activated and cause a general down-regulation of most skeletal muscle ECC genes 
and the reversal to a more “foetal-like” muscle. It is difficult to understand how and 
why such epigenetic modifications are activated but they may relate to the fact that of 
phosphoinositide lipids have a negative effect on ECC, on SR structure and 
consequently on muscle function. The lack of normal Ca2+ homeostasis in skeletal 
muscle could affect its physiological development further precluding its proper 
function. If this is the case, then it is possible that patients with such congenital 
myopathies may show benefit from pharmacological compounds targeted to decrease 
the expression levels of class II HDACs. 
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MATERIALS AND METHODS 
Muscle biopsies and cell cultures: Human myoblasts from controls and patients were 
cultured in skeletal muscle growth medium as previously described (34, 36, 39, 41) 
until approximately 90% confluent then they were induced to differentiate by 
switching the medium to differentiation medium (PromoCell; C-23061) for 7 days.  
Calcium measurements: Muscle cells were cultured on laminin-coated 0.17 mm glass 
cover slips as previously described (34, 39, 42). Fully differentiated myotubes were 
loaded with 5 µM fura-2/AM (Calbiochem; 344905) for 30 min at 37° C and mounted 
on a temperature-controlled stage (tempcontrol 37-2 digital). The chamber was 
continuously perfused with Krebs-Ringer medium containing 2 mM Ca2+ and cells 
were stimulated using a 12-way 100 mm diameter quartz micro-manifold computer-
controlled microperfuser (ALA Scientific Instruments), as described previously (39, 
41, 42). Recordings were done on a fluorescent Axiovert S100 TV inverted 
microscope (Carl Zeiss) equipped with a 20x water-immersion FLUAR objective (NA 
0.17) and filters (BP 340/380, FT 425, BP 500/530) attached to a Photometrics 
Cascade 128+ CCD (charge-coupled device) camera controlled by VisiView software 
version 2.0.8. Data analysis was performed using ImageJ version 1.50g and the Ratio 
Plus, Process Fura2, Time Series Analyzer V 3 plugins. 
Brightfield and confocal microscopy: Muscle cells were cultured on laminin-coated 
Ibidi® 0.17 mm µ-Slide 4 well glass bottom slides (Ibid Cat # 80427) until 90% 
confluent. The medium was switched to differentiation medium for 7 days after which 
cells were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) and 
visualized using a Nikon TE2000 TIRF microscope equipped with a 20x Plan Apo air 
objective and attached to an electron multiplier Hamamatsu CCD camera C9100-13.  
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For cell size and nuclear counting, cells were stained with 4',6-diamidino-2-
phenylindole (DAPI) and observed with a Nikon A1plus confocal microscope 
equipped with a Plan Fluor 20x air objective (NA 0.75); calculation of the cell area 
was performed using the Fiji software (version 2.0.0-rc-49/1.51d) as described (61). 
For immunofluorescence, cells were permeabilized with 1% Triton® X-100 in PBS 
for non-lipophilic targets (myotubularin, RyR1, CaV1.1) and 0.01% Digitonin 
(Calbiochem; 300411) in TRIS buffered saline (TBS) for lipophilic targets (PI3P, 
PI(3,4)P2). Non-specific binding sites were blocked by 1% blocking buffer in TBS 
(Roche; 11500694001). Cells were incubated with the primary antibodies detailed in 
Supplementary Table 3 for 60 min at room temperature, rinsed three times with 0.1% 
Tween® 20 in TRIS buffered saline (TBS-T) for non-lipophilic targets; for lipophilic 
targets antibodies were incubated at 37°C and washed with 0.1% blocking buffer in 
PBS. Cells were then incubated for 60 min at room temperature with the appropriate 
Alexa Fluor conjugated secondary antibodies (Life technologies). Actin filaments 
were stained for 30 minutes using phalloidin conjugated Alexa Fluor® 647 and nuclei 
were counterstained with DAPI. Myotubes were visualized on a Nikon® A1plus 
confocal microscope equipped with a Nikon Plan Apo TIRF 60x oil objective (NA 
1.49) and with Coherent® Sapphire lasers (405, 488, 561 nm) and an MPBC® CW 
Visible Fiber laser (647 nm) controlled by Nikon® NIS-Elements Confocal software.  
Electrophoresis and immunoblotting: Total homogenates of muscle biopsies and 
myotubes were prepared as previously described (34, 39). Protein concentration was 
determined using the Bradford protein assay kit (Bio-Rad, 500-0006) using bovine 
serum albumin as a standard. Proteins (50 µg/lane) were separated on 6 or 7.5% SDS-
PAGE and blotted onto nitrocellulose. For MyHC isoform separation, gels were 
prepared according to Talmadge and Roy (40) and stained with Coomassie Blue R250 
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(Fluka; 27816). Single fibres isolated from mouse FDB or soleus fibres were used to 
identify the different MyHC isoforms; alternatively in order to verify whether 
embryonic/neonatal isoforms were present, proteins were transferred onto 
nitrocellulose and stained with anti-MyHC3 followed by anti-MyHC recognizing all 
isoforms. For immunoblotting, membranes were blocked for 60 minutes at room 
temperature or overnight at 4°C in 1% blocking buffer (Roche; 11500694001) and 
incubated with the primary antibodies listed in Supplementary Table 3. Secondary 
antibodies/proteins used were either anti-mouse peroxidase (Sigma, catalogue 
#A2304) or protein-G peroxidase (Sigma, catalogue # P8170). Bands were visualized 
using the SuperSignal Dura West kit (Thermo Scientific; 34076) or BM 
Chemiluminescence kit (Roche; 11520709001). For quantification, films were 
scanned on an Epson Perfection V700 Photo as 16-bit tiff image and densiometrically 
analysed using the GelAnalyzer software version 2010a. 
Quantitative PCR: RNA was extracted from muscle biopsies using TRIzol® reagent 
(Thermo Fischer; 15596026) according to the manufacturer’s instructions. DNA was 
removed using DNase I (Invitrogen; 18068-015) and 1000 ng RNA were reverse-
transcribed into cDNA using the High capacity cDNA Reverse Transcription Kit 
(Applied Biosystems; 4368814) on an Applied Biosystems 2720 Thermal Cycler. The 
cDNA was amplified by quantitative real-time polymerase chain reaction (qPCR) 
using either Power Sybr® Green Master Mix (Applied Biosystems; 4367659) for 
regular DNA quantification or TaqMan® microRNA reverse transcription kit (Applied 
Biosystems; 4366596) for miRNA assays both on an Applied Biosystems 7500 Fast 
Real-time PCR System running 7500 software version 2.3 (34). Quantification was 
based on the comparative ∆∆Ct method. The sequences of the primers used for qPCR 
are listed in Supplementary Table 4 and the sequences of primers used for miRNA 
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quantification are listed in Supplementary Table 5. Each reaction was performed in 
triplicate and results are expressed as relative gene expression normalized to desmin 
(DES) for qPCR and to the human housekeeping gene RNU44 for miRNAs. 
Expression levels obtained from biopsies of healthy controls were set to 1. 
PIP lipid quantification: The content of PI3P and PI(4,5)P2 was determined on 
muscle biopsies from patients and controls using the Mass ELISA kits (Echelon 
catalogue numbers K-3300 and K-4500), following the manufacturers 
recommendations. For each muscle, the content of PI3P was calculated either as 
[PI3P] per gram of wet weight or was normalized to the content of PI(4,5)P2 which is 
reported to be constant in most tissues (62). 
Compliance with Ethical standards: All procedures performed in studies involving 
human participants were in accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki declaration and its 
later amendments or comparable ethical standards. This study was approved by the 
Ethikkommission beider Basel (permit N° EK64/12); all subjects gave written 
informed consent to carry out this work.  
Statistical analysis: Statistical analysis was performed using the 'R' version 3.2.4 
running on platform x86_64-apple-darwin13.4.0 (64-bit). For dose-response curves 
the package 'drc' version 2.5-12 was used  (63). Comparisons of two groups were 
performed using the Student's t-test, for groups of three or more comparisons were 
made using the ANOVA test followed by the Bonferroni post-hoc test unless 
otherwise stated. Means were considered statistically significant when P values were 
< 0.05. All figures were created using Adobe Photoshop CS6 or R Studio (version 
0.99.891 or newer).  
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LEGENDS TO FIGURES  
Figure 1: Myotubes from XLMTM patients are smaller and have fewer nuclei 
than myotubes from healthy controls. A. Brightfield image overlaid with DAPI 
staining to visualize nuclei. Top panel shows myotubes from a healthy control, 
bottom panel, from a patient with XLMTM; bar indicates 50µm. B Mean (±SEM) 
myotube area and C. mean (±SEM) number of nuclei / myotube was significantly 
higher in cells from controls (total number of cells measured = 41) compared to cells 
from XLMTM patients (total number of cells measured = 16). D. The calculated ratio 
of number of nuclei/cell area was not different. Cells were prepared as described in 
the Materials and Methods section, fixed with paraformaldehyde and stained with 
DAPI to visualize nuclei with a Plan Fluor 20x air objective (NA 0.75).  **P <0.01 
Student’s t test. 
Figure 2: The subcellular distribution of PI3P and PI(3,4)P2 in myotubes is 
similar in cells from XLMTM patients and healthy controls. Human skeletal 
muscle myotubes were stained as described in the Material and Methods section and 
analyzed using a Nikon A1 plus confocal microscope equipped with a Nikon Plan 
Apo TIRF 60x oil objective (NA 1.49). (A). Subcellular distribution of PI3P in 
myotubes from a healthy control (a) and an XLMTM patient (c). Subcellular 
distribution of PI(3,4)P2 in myotubes from a healthy control (e) and an XLMTM 
patient (g). Composite images showing the distribution of PI3P (red), actin (green) 
and nuclei (blue) in myotubes from a healthy control (b) and an XLMTM patient (d). 
Composite images showing the distribution of PI(3,4)P (red), actin (green) and nuclei 
(blue) in a myotube from a healthy control (f) and an XLMTM patient (h). The 
background staining on areas of the coverslip devoid of cells may be caused either by 
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lipid aggregates or by fragments of membranes of cells that have detached. Also note 
that the subcellular distribution of the two phospholipids is different: PI3P has a 
punctuate uniform intracellular membrane distribution whereas PI(3,4)P2 appears to 
be more clustered within intracellular membranes. Bar indicates 50 µm. (B). Bar chart 
showing the mean (±S.E.M.) fluorescence intensity (arbitrary units, a.u.) associated 
with PI3P and PI(3,4)P2 in myotubes from a control and XLMTM patient. *P<0.05 
Student’s t test.  
Figure 3:  Cellular distribution and quantification of RyR1 and Cav1.1 in 
differentiated myotubes from XLMTM patients and healthy controls. (A). 
Confocal analysis of subcellular distribution of RyR1 and Cav1.1 in myotubes. 
Human myotubes were visualized with a Nikon A1 plus confocal microscope 
equipped with a Plan Apo 60x oil objective (NA 1.49) and stained as described in the 
Materials and Methods section. Top panels show myotubes from a healthy control, 
bottom panels show myotubes from an XLMTM patient. Panels (a) and (d) anti-
RyR1, panels (b) and (e) anti-Cav1.1. Panels (c) and (f) composite image of anti-
RyR1 (red), anti-CaV1.1 (green) and DAPI (blue); orange pixels show area where 
RyR1 and Cav1.1 co-localize. Bar indicates 50 µm. (B). Representative immunoblots 
of myotubes from a control and XLMTM patient. Blots were probed with the 
indicated primary antibodies. (C). Relative content of the immunopositive band 
(normalized to MyHC) of HDAC-4, RyR1, Cav1.1 and myotubularin (MTM1) in 
myotubes from controls (full circles) and XLMTM patients (empty circles). 
**Student’s t test P<0.01; n.s. not significantly different. NA, not applicable. 
Figure 4:  Calcium homeostasis in human skeletal muscle-derived myotubes 
from XLMTM patients and healthy controls. (A). Resting [Ca2+]i. Bars represent 
the mean (±SEM) resting [Ca2+] calculated from the indicated number of cells. 
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Myotubes from XLMTM patients had significantly lower resting [Ca2+]i than 
myotubes from healthy controls. ***P<0.001 Student’s t test. (B). Total amount of 
Ca2+ in the SR. Bars represent the mean (± SEM) fluorescence obtained by calculating 
the Area Under the Curve (AUC) after stimulation of cells with 1 µM ionomycin + 1 
µM thapsigargin in Krebs Ringer containing 0.5 mM EGTA. (C). Representative 
trace showing changes in [Ca2+]i induced by stimulation with 60 mM KCl. (D). Peak 
(mean ± SEM) response to 600 µM 4-chloro-m-cresol and (E) 60 mM KCl. 
Experiments were performed as indicated in the Materials and Methods section in 
Krebs-Ringer containing 100 µM La3+ unless otherwise stated. n.s. results were not 
significantly different. 
Figure 5: Western blot analysis, protein quantification and qPCR analysis of the 
two main calcium channels involved in skeletal muscle EC coupling, of class II 
HDACs and DNA methyltransferases in muscle biopsies from XLMTM patients 
and healthy controls. (A) and (C) Representative immunoblots probed with the 
indicted antibodies. Lanes 1 and 3, muscle extracts from a healthy control, lanes 2 and 
4, muscle extracts from an XLMTM patient. Lower blots show immunoreactivity to 
an antibody recognizing all MyHC isoform used to normalize for protein loading. (B) 
and (D) Comparison of the relative expression of the indicated proteins in muscle 
extracts of the available patients; healthy controls (full circles), XLMTM patients 
(empty circles). Statistical analysis was performed using the Welch two sample test. * 
P<0.05 and **P<0.01. (E). Transcript levels of the DNA methylating enzymes 
DNMT1 and TRDMT1 (previously known as DNMT2) were significantly elevated in 
muscles of patients versus controls. (F). Gene expression was performed by qPCR as 
described in the Materials and Methods section and with the primer sequences given 
in Supplementary Table 4. Each reaction was performed in triplicate on muscle 
 38 
biopsies from healthy controls and XLMTM patients and expression levels were 
normalized to DES. Results were prepared using Excel’s “Conditional Formatting 
Plugin” using the 3-scale color specified in the last column. Relative transcript 
content in patients was compared to that found in healthy controls that was set to 1.  
Figure 6: qPCR analysis of selected microRNAs in muscle biopsies from healthy 
controls versus XLMTM patients. Top panel: each reaction was performed in 
triplicate on muscle biopsies from healthy controls (full circles) or XLMTM patients 
(empty circles). Expression levels were normalized to RNU44 expression. Bottom 
panel: predicted binding partner(s) of the quantified miRNA and statistical analysis 
(Student’s t test) of changes in levels of expression between healthy controls and 
XLMTM patients. 
Figure 7: Muscle biopsies from foetuses express lower levels of RyR1, different 
MyHC isoforms and variable levels of class II HDACs compared to muscles of 
older healthy controls. (A). Quantification of HDAC-4 and HDAC-5 and (B) 
quantification of RyR1 and Cav1.1 in total muscle homogenates from healthy controls 
(full circles) and foetal muscles (empty circles). Statistical analysis was performed 
using the Welch two sample test. **P<0.01; n.s. not significantly different. (C). 
Electrophoretic separation of MyHC isoforms performed according to Talmadge and 
Roy (40). (D). Representative Western blots showing the immunoreactivity of the 
muscle homogenates with an antibody recognizing the embryonic/foetal isoform 
(MyHC 3, top) and an antibody recognizing all MyHC isoforms (bottom).  
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Table 1: Genotype and phenotype of the patients investigated in the present 
study 
Sample ID Disease 
severity 
Phenotype Exon MTM1 
mutation 
Amino acid 
substitution 
NH15-0805 Severe Ventilator dependent aged 18 
months. 
11 c.1084_1087
delGACA  
p.Asp362fs 
6212 Severe Died aged 4 months 11 c.1171T>G  p.Tyr397X 
NH13-0078 Severe Died age of 6 months, Bipap 
ventilated. 
8 c.594C>G  p.Tyr198X 
6499 Moderate Neonatal nasogastric tube 
requirement and gastrostomy 
and one year. Ventilation not 
required, but marked orobulbar 
secretions difficulties. Died at 3 
years 10 months age. 
14  c.1508_1509
delAC 
 
7457 Moderate/ 
Severe  
Non-invasive mask ventilation 
at 3 months, tracheostomy by 1 
year. 24 hour tracheostomy 
ventilation dependent at age 12 
years. 
1 deletion 
exon1 and 5' 
part of gene 
 
NH14-1816 Severe Ventilator dependent via 
tracheostomy aged 2 years. No 
head control or sitting ability. 
9 c.721C>T  p.Arg241Cys 
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ABBREVIATIONS: alfa 1 subunit of the dihydropyridine receptor, Cav1.1; 
dihydropyridine receptor, DHPR; excitation-contraction coupling, ECC; histone de-
acetylase, HDAC; micro RNAs, miRs; myotubularin, MTM1; myosin heavy chain, 
MyHC; PI, phosphoinositide; PIP, phosphoinositide phosphate; ryanodine receptor 1, 
RyR1; sarcoplasmic reticulum, SR; X-linked myotubular myopathy, XLMTM. 
 
